Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949234 · ClinicalTrials.gov registry record · Phase 2
Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT00949234 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 267 participants.
The verdict
NCT00949234, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
The purpose of this program is to evaluate an effort to provide a comprehensive package of HIV prevention services of which post-exposure prophylaxis (medicines that may help prevent HIV infection after an exposure) can be a part. It will also include risk reduction information and testing for other sexually transmitted infections.
Interventions
- DRUG tenofovir + emtricitabine, lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949234
The ClinicalTrials.gov registry entry for NCT00949234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tenofovir + emtricitabine, lopinavir/ritonavir is the first listed.
NCT00949234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00949234 about?
NCT00949234 is a clinical study titled "Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV". The purpose of this program is to evaluate an effort to provide a comprehensive package of HIV prevention services of which post-exposure prophylaxis (medicines that may help prevent HIV infection after an exposure) can be a part. It will also include risk reduction information and testing for other...
What is the current status of trial NCT00949234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2010-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00949234?
The interventions under investigation include: tenofovir + emtricitabine, lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00949234?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.